

# KEAP1 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP10092b

## **Product Information**

Application	WB, IHC-P, E
Primary Accession	<u>Q14145</u>
Other Accession	<u>Q684M4</u> , <u>NP_036421.2</u> , <u>NP_987096.1</u>
Reactivity	Rat, Human
Predicted	Pig
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB28438
Calculated MW	69666
Antigen Region	422-449

### **Additional Information**


Gene ID	9817
Other Names	Kelch-like ECH-associated protein 1, Cytosolic inhibitor of Nrf2, INrf2, Kelch-like protein 19, KEAP1, INRF2, KIAA0132, KLHL19
Target/Specificity	This KEAP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 422-449 amino acids from the C-terminal region of human KEAP1.
Dilution	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	KEAP1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**


Name	KEAP1 {ECO:0000303 PubMed:14585973, ECO:0000312 HGNC:HGNC:23177}
Function	Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase

	complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973, PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:37339955). KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes (PubMed:15601839, PubMed:16006525). In response to oxidative stress, different electrophile metabolites trigger non-enzymatic covalent modifications of highly reactive cysteine residues in KEAP1, leading to inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:19489739, PubMed:29590092). In response to selective autophagy, KEAP1 is sequestered in inclusion bodies following its interaction with SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1) complex also targets BPTF and PGAM5 for ubiquitination and degradation by the proteasome (PubMed:15379550, PubMed:17046835).
Cellular Location	Cytoplasm. Nucleus. Note=Mainly cytoplasmic (PubMed:15601839). In response to selective autophagy, relocalizes to inclusion bodies following interaction with SQSTM1/p62 (PubMed:20452972).
Tissue Location	Broadly expressed, with highest levels in skeletal muscle.

#### Images



KEAP1 Antibody (C-term) (Cat. #AP10092b) western blot analysis in HepG2 cell line lysates (35ug/lane).This demonstrates the KEAP1 antibody detected the KEAP1 protein (arrow).



KEAP1 antibody (C-term) (Cat. #AP10092b) immunohistochemistry analysis in formalin fixed and paraffin embedded human skeletal muscle followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the KEAP1 antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.